Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 11, 2022 12:41 ET | Source: Euro Manganese Inc.

Euro Manganese beginnt mit Inbetriebnahme von Demonstrationsanlage

VANCOUVER, British Columbia, Nov. 11, 2022 (GLOBE NEWSWIRE) -- Euro Manganese Inc. (TSX-V und ASX: EMN; OTCQX: EUMNF; Frankfurt: E06) (das „Unternehmen“ oder „EMN“) freut sich, den Beginn der...
November 10, 2022 18:35 ET | Source: Euro Manganese Inc.

Euro Manganese Commences Demonstration Plant Commissioning

VANCOUVER, British Columbia, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Euro Manganese Inc. (TSX-V and ASX: EMN; OTCQX: EUMNF; Frankfurt: E06) (the "Company" or "EMN") is pleased to announce the commencement...
November 10, 2022 16:31 ET | Source: 5E Advanced Materials, Inc.

5E Advanced Materials Reports First Quarter 2023 Results

HIGHLIGHTS Small-Scale Boron Facility ("SSBF") on target for mechanical completion in CY 2022Board enhanced by appointment of three U.S. based directors with global industry experienceResearch...
November 10, 2022 16:01 ET | Source: AVITA Medical

AVITA Medical Reports Third Quarter 2022 Financial Results

VALENCIA, Calif. and MELBOURNE, Australia, Nov. 10, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “Company”), a regenerative medicine company leading the development and...
November 10, 2022 11:10 ET | Source: Immutep Limited

Immutep Announces Compelling Clinical Results from Phase II Trial Utilizing its First-in-Class Soluble LAG-3 Protein, Eftilagimod Alpha, in 1st Line NSCLC at SITC 2022 Annual Meeting

Media Release Overall response rate (ORR) increases to 40.4%, according to iRECIST, in TACTI-002 all-comer PD-L1 Phase II trial in 1st line non-small cell lung cancer (1L NSCLC) ORR improved across...
November 10, 2022 09:00 ET | Source: Immutep Limited

Immutep Announces Promising Initial Clinical Data from INSIGHT-003 at SITC 2022

Media Release First activity evaluation of efti as part of triple combination therapy yields promising early results with 72.7% response rate and 90.9% disease control rate in 1st line NSCLC...
November 10, 2022 08:00 ET | Source: Genetic Technologies Ltd

Webinar - Dr Erika Spaeth to interview A/Prof Charles Siles on risk assessment tests for serious disease

MELBOURNE, Australia, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies (ASX:GTG, NASDAQ:GENE), a global leader in guideline driven Genomics based tests in health, wellness and serious disease...
November 10, 2022 06:00 ET | Source: Opthea Limited

Opthea to Present at Jefferies London Healthcare Conference

MELBOURNE, Australia, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and...
November 09, 2022 18:45 ET | Source: AVITA Medical

AVITA Medical Announces Achievement of Co-Primary Endpoints in Updated Analysis of Pivotal Trial of RECELL® System for Soft Tissue Repair

VALENCIA, Calif. and MELBOURNE, Australia, Nov. 09, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and...
November 09, 2022 09:00 ET | Source: Patriot Battery Metals

Patriot Battery Metals Lodges ASX Prospectus

VANCOUVER, British Columbia, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Patriot Battery Metals Inc. (the “Company” or “Patriot”) (TSX-V: PMET) (OTCQB: PMETF) (FSE: R9GA) is pleased to provide an update in...